MBX Biosciences (MBX) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Right. Good afternoon, everyone. Thank you Speaker1 for joining us on our next session. I'm Michael Yee, a biotechnology analyst at Jefferies. I am really pleased to have members of the team from MBX here with us, CEO Kent Harlock, as well as CMO Sam Azole. And importantly, the company is going Speaker0 to give a brief overview Speaker1 of what's going on at MBX. And obviously, I'm very excited about the upcoming data in the third quar ...

Summary of MBX Biosciences Conference Call Company Overview - **Company**: MBX Biosciences - **Industry**: Clinical stage biopharmaceuticals focusing on peptide technology - **Key Technology**: Precision Endocrine Peptide (PEP) technology platform aimed at optimizing peptide therapies for endocrine diseases [3][4] Core Points and Arguments - **Financial Position**: MBX has $2.24 billion in funding as of the last quarter, expected to support operations until mid-2027 [4][5] - **Lead Indication**: Focus on chronic hypoparathyroidism (HP), affecting over 250,000 people in the US and EU [7] - **Current Treatment Landscape**: Standard care involves high doses of vitamin D and calcium supplements, which do not address the underlying PTH deficiency [8][9] - **New Therapy**: Camboparatide (CANVU) is a once-weekly PTH replacement therapy designed to improve patient convenience and outcomes compared to existing treatments [10][21] - **Phase One Data**: Positive results showing dose-dependent increases in serum calcium and a long half-life of 8-9 days, supporting once-weekly dosing [14][16] - **Phase Two Trial Design**: A 12-week trial with a fixed dose period followed by dose adjustments, aiming for a statistically significant treatment response rate of at least 55% [19][21] Competitive Landscape - **Market Entry**: The launch of Yorvy Path, a once-daily PTH replacement therapy, is seen as a positive development, with initial sales of approximately $50 million [26] - **Patient Demand**: There is significant demand for PTH replacement therapy among HP patients, who often feel inadequately managed on current supplements [27][28] Other Pipeline Programs - **Post-Bariatric Hypoglycemia (PBH)**: MBX is developing a long-acting GLP-1 antagonist for PBH, a condition with no approved pharmacotherapy, targeting a market comparable in size to HP [30][31] - **Obesity Program**: A new obesity treatment (4291) is in development, aiming for once-monthly dosing and improved tolerability compared to existing therapies like tirzepatide [38][40] Additional Insights - **Patient-Centric Approach**: The company emphasizes patient needs and aims to provide more effective treatment options [26][27] - **Regulatory Progress**: Plans to file an IND for the obesity program within the current quarter [43] - **Future Milestones**: The upcoming phase two results for CANVU are viewed as a transformative milestone for both the company and the field of HP treatment [24][44]